Mesa Laboratories Q3 revenue rises 3.6%

Overview

• Life science tools maker's fiscal Q3 revenue rose 3.6% yr/yr

• Operating income for fiscal Q3 increased 38%

• Company repaid $8.7 mln of debt, reducing leverage ratio to 2.62

Outlook

• Mesa expects positive momentum to continue in 4Q26

• Company anticipates slight moderation in profitability margins over next quarters

• Mesa expects CG division to return to positive organic growth in 4Q26

Result Drivers

• BIOPHARMACEUTICAL DEVELOPMENT - Strong growth driven by higher sales of Immunoassays and Peptides instruments

• STERILIZATION AND DISINFECTION CONTROL - Growth due to higher sales volumes and modest price increases

• CLINICAL GENOMICS CHALLENGES - Revenue contraction in China due to regulatory and tariff headwinds

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Mesa Laboratories Inc is $99.00, about 23% above its February 2 closing price of $80.50

• The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 44 three months ago

Press Release: ID:nGNX4gZPqx

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.